Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study
Journal of Clinical Medicine · 18.07.2026 · 15 (14) · 5650
DOI: 10.3390/jcm15145650 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.07.2026. Verfasst von Rushi Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Background/Objectives: Fixed-dose triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) at high risk of exacerbations; however, direct comparative effectiveness data between available triple therapy regimens remain limited. We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR).
Methods
We conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults with a spirometrically confirmed diagnosis of COPD who received fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR) between July 2020 and August 2024 were included in the analysis. A 365-day landmark period was applied to establish maintenance therapy, with outcome follow-up beginning 1 year after treatment initiation. Patients were followed for outcomes through August 2025, the date of database analysis. After 1:1 propensity score matching, treatment groups were compared for COPD exacerbations, acute respiratory failure (ARF), hospitalization, and all-cause mortality using RR and Cox proportional hazards analyses.
Results
In matched cohorts, FF/VI/UMEC was associated with a significantly higher risk of COPD exacerbations (5.6% vs. 3.9%; RR 1.44; 95% CI 1.30–1.59; p < 0.001) and ARF (2.5% vs. 1.9%; RR 1.28; 95% CI 1.11–1.46; p < 0.001) compared with BUD/GLY/FOR. Time-to-event analyses demonstrated lower event-free probability for exacerbations (HR 1.35; (95% CI 1.21–1.50) and ARF (HR 1.15; (95% CI 1.00–1.32))). All-cause mortality was numerically higher in the FF/VI/UMEC cohort (5.2% vs. 4.7%; RR 1.09; 95% CI 1.00–1.19; p = 0.050); however, time-to-event analysis did not demonstrate a statistically significant difference. Hospitalization rates were similar between groups.
Conclusions
In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA.
- Department of Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.
- Department of Medicine, GMERS Medical College and Hospital, Valsad 396001, Gujarat, India.
- Department of Internal Medicine, WVU Camden Clark Medical Center, Parkersburg, WV 26101, USA.
- Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Rushi Patel, Jacob Thompson, Namra Patel, Abhi C Lohana, Subhash Chander, Viral Patel
Zitieren
APA
Patel, R., Thompson, J., Patel, N., Lohana, A. C., Versha, F., Chander, S., Patel, V., & Iribarren, J. (2026). Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. Journal of Clinical Medicine, 15(14), 5650. https://doi.org/10.3390/jcm15145650
Vancouver
Patel R, Thompson J, Patel N, Lohana AC, Versha F, Chander S, et al. Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. Journal of Clinical Medicine. 2026;15(14):5650. doi:10.3390/jcm15145650
BibTeX
@article{Patel2026,
author = {Patel, Rushi and Thompson, Jacob and Patel, Namra and Lohana, Abhi C and Versha, Fnu and Chander, Subhash and Patel, Viral and Iribarren, Juan},
title = {Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5650},
doi = {10.3390/jcm15145650}
}
EUVIMED